Long Term Follow-up Data and Health-Related Quality of Life in Frontline Therapy of Fit Patients Treated With FCR Versus BR (CLL10 Trial of the GCLLSG).

Hemasphere · 2020 · PMC7000471 · PMID 32072150

Europe PMC DOI

hedged sentence

0.1730

closest p · 3.5× alpha

0.1730

boldest claim

The sentences

did not reach statistical significancep = 0.173not close (p > 0.1)

The shorter PFS observed with BR in patients with mutated IGHV did not reach statistical significance in comparison to the FCR treated group (68.9 months vs not reached; HR 1.356; 95% CI 0.872–2.137; p = 0.173) (Fig. 1 C).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.